Share this

Article Facebook

Twitter

Email You are free to share this article under the Attribution 4.0 International license. University Rice University

A nanofiber hydrogel infused with snake venom may be the best material to stop bleeding quickly—and may perform better than anticoagulants, a new study suggests.

The hydrogel called SB50 incorporates batroxobin, a venom produced by two species of South American pit viper. It can be injected as a liquid and quickly turns into a gel that conforms to the site of a wound, keeping it closed, and promotes clotting within seconds.

The findings suggest the hydrogel may be most useful for surgeries, particularly for patients who take anti-coagulant drugs to thin their blood.

“It’s interesting that you can take something so deadly and turn it into something that has the potential to save lives.”

The hydrogel may be most useful for surgeries, particularly for patients who take anti-coagulant drugs to thin their blood.

“It’s interesting that you can take something so deadly and turn it into something that has the potential to save lives,” says Jeffrey Hartgerink, a chemist at Rice University.

Batroxobin was recognized for its properties as a coagulant—a substance that encourages blood to clot—in 1936. It has been used in various therapies as a way to remove excess fibrin proteins from the blood to treat thrombosis and as a topical hemostat. It has also been used as a diagnostic tool to determine blood-clotting time in the presence of heparin, an anti-coagulant drug.

“From a clinical perspective, that’s far and away the most important issue here,” Hartgerink says. “There’s a lot of different things that can trigger blood coagulation, but when you’re on heparin, most of them don’t work, or they work slowly or poorly. That obviously causes problems if you’re bleeding.

“Heparin blocks the function of thrombin, an enzyme that begins a cascade of reactions that lead to the clotting of blood,” he says. “Batroxobin is also an enzyme with similar function to thrombin, but its function is not blocked by heparin. This is important because surgical bleeding in patients taking heparin can be a serious problem. The use of batroxobin allows us to get around this problem because it can immediately start the clotting process, regardless of whether heparin is there or not.”

Works in 6 seconds

The batroxobin combined with the hydrogels isn’t taken directly from snakes, Hartgerink says. The substance used for medicine is produced by genetically modified bacteria and then purified, avoiding the risk of other contaminant toxins.

For the study, published in ACS Biomaterials Science and Engineering, researchers combined batroxobin with their synthetic, self-assembling nanofibers, which can be loaded into a syringe and injected at the site of a wound, where they reassemble themselves into a gel.

Tests showed the new material stopped a wound from bleeding in as little as six seconds, and further prodding of the wound minutes later did not reopen it. The researchers also tested several other options: the hydrogel without batroxobin, the batroxobin without the hydrogel, a current clinical hemostat known as GelFoam and an alternative self-assembling hemostat known as Puramatrix and found that none were as effective, especially in the presence of anti-coagulants.

The new work builds upon extensive development of injectable hydrogel scaffolds that help wounds heal and grow natural tissue. The synthetic scaffolds are built from the peptide sequences to mimic natural processes.

“To be clear, we did not discover nor do any of the initial investigations of batroxobin,” Hartgerink says. “Its properties have been well-known for many decades. What we did was combine it with the hydrogel we’ve been working on for a long time.

“We think SB50 has great potential to stop surgical bleeding, particularly in difficult cases in which the patient is taking heparin or other anti-coagulants,” he says. “SB50 takes the powerful clotting ability of this snake venom and makes it far more effective by delivering it in an easily localized hydrogel that prevents possible unwanted systemic effects from using batroxobin alone.”

SB50 will require FDA approval before clinical use, Hartgerink says. While batroxobin is already approved, the hydrogel has not yet won approval, a process he expects will take several more years of testing.

The National Institutes of Health and the Welch Foundation supported the research.

Source: Rice University